证券代码：301301 证券简称：川宁生物 公告编号：2025-041 伊犁川宁生物技术股份有限公司 关于预计公司2026年度日常关联交易情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 本公告所涉公司日常关联交易是指伊犁川宁生物技术股份有限公司及子公 司（以下统称"公司"）与关联方四川科伦药业股份有限公司（以下简称"科伦 药业"）及其下属子公司（以下统称"科伦药业集团"）发生的采购及销售商品、 接受及提供劳务；与关联方伊犁恒辉淀粉有限公司（以下简称"恒辉淀粉"）发 生的委托加工原材料和材料采购；与关联方伊犁顺鸿生态农业科技开发有限公司 （以下简称"伊犁顺鸿"）发生的销售商品；与关联方河北国龙制药有限公司（以 下简称"河北国龙"）发生的销售产品所形成的关联交易。 公司预计2026年度与科伦药业集团发生的日常关联交易金额合计不超过 28,360.00万元；与恒辉淀粉发生的日常关联交易金额合计不超过9,300.00万元； 与伊犁顺鸿发生的日常关联交易金额合计不超过1,900.00万元；与河北国龙发生 的日 ...

证券代码：301301 证券简称：川宁生物 公告编号：2025-044 伊犁川宁生物技术股份有限公司 关于召开2026年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 根据《中华人民共和国公司法》和《伊犁川宁生物技术股份有限公司章程》 （以下简称"《公司章程》"）等有关规定，经伊犁川宁生物技术股份有限公司（以 下简称"公司"）第二届董事会第十三次会议审议通过了《关于召开公司 2026 年第一次临时股东会的议案》，公司董事会决定于 2026 年 1 月 9 日（星期五）召 开公司 2026 年第一次临时股东会。现就本次会议有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：公司董事会 3、会议召开的合法性及合规性：本次股东会召集程序符合有关法律、行政 法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开的日期及时间： （1）现场会议召开时间：2026 年 1 月 9 日 15:00 （2）网络投票时间： ①通过深圳证券交易所交易系统进行网络投票的具体时间为：2026 年 ...

证券代码：301301 证券简称：川宁生物 公告编号：2025-043 伊犁川宁生物技术股份有限公司 第二届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 伊犁川宁生物技术股份有限公司（以下简称"公司"）第二届董事会第十三 次会议通知于 2025 年 12 月 15 日以专人送达、电子邮件和电话通知的方式发出， 会议于 2025 年 12 月 23 日上午 10 点以通讯的表决方式召开。会议应出席董事 7 人，实际出席董事 7 人，会议由董事长刘革新先生主持，公司全体高级管理人员 列席了会议。本次会议的召集和召开程序符合《中华人民共和国公司法》（以下 简称"《公司法》"）等有关法律、行政法规、部门规章、规范性文件和《公司 章程》的相关规定，会议形成的决议合法、有效。 二、董事会会议审议情况 （二）以 7 票同意，0 票反对，0 票弃权，审议通过了《关于部分募投项目 结项并将节余募集资金用于其他募投项目建设的议案》 经审议，同意公司将"上海研究院建设项目"结项，并将节余募集资金用于 "绿色循环产业园项目"。本次 ...

Group 1 - A-shares and Hong Kong stocks experienced a significant rebound, with the Shanghai Composite Index rising by 1.19% and the Hang Seng Index increasing by 0.92% [1] - The largest medical ETF in the market (512170) and the only drug ETF (562050) both rose over 1%, indicating a broad recovery in the medical sector [1] - The medical ETF (512170) showed a strong technical signal with a "bullish engulfing" pattern, suggesting a potential trend reversal [1] Group 2 - The pharmaceutical sector in A-shares also saw a surge, with the drug ETF (562050) rising by 1.19%, driven by contributions from innovative and traditional Chinese medicine stocks [3] - The drug ETF (562050) has approximately 25% weight in traditional Chinese medicine, which helps mitigate the volatility of the overall pharmaceutical index [3] Group 3 - The Hong Kong innovation drug sector is showing signs of recovery, with the Hong Kong innovation drug ETF (520880) successfully closing in the green, attracting "bottom-fishing" funds [5] - The fund size of the Hong Kong innovation drug ETF (520880) reached a new high of 4.172 billion shares, reflecting strong investor interest [5] Group 4 - The A+H pharmaceutical sector has been in a correction phase for three months, and analysts suggest that this may be an opportune time for medium to long-term investments in pharmaceutical assets [8] - Recent positive developments in the pharmaceutical industry include overseas collaborations and increasing demand for CXO services, indicating a favorable outlook for the sector [9] Group 5 - The fund manager of the Hong Kong innovation drug ETF (520880) maintains a balanced allocation strategy, highlighting the potential for recovery in the innovative drug industry and related sectors [10] - New investment tools, such as the Hong Kong medical ETF (159137), are being launched to track the medical innovation theme, covering various core leaders in the medical field [7]

Core Viewpoint - Chuaning Bio, a leading company in the domestic bio-fermentation technology sector, has extended the lock-up period for its pre-IPO shares held by its controlling shareholder, Sichuan Kelun Pharmaceutical, until December 27, 2026, to enhance investor confidence and stabilize the capital market [1] Group 1: Shareholder Commitment - The lock-up extension involves approximately 1.61 billion shares, accounting for 72.19% of the company's total share capital [1] - This commitment reflects the controlling shareholder's confidence in the company's future development and intrinsic value [1] Group 2: Production and Market Outlook - Chuaning Bio reported that its three major intermediates are operating at full capacity, although the overall shipment volume has decreased by about 8% year-on-year [2] - The company anticipates a potential recovery in market demand for penicillin products, with prices currently at historical lows, and expects a positive trend as the traditional peak season approaches [2] - The company has initiated a collaboration with Shanghai Jincheng Technology to leverage AI in enhancing production efficiency in bio-fermentation [2] Group 3: AI and Product Development - The AI virtual engineer has shown an average production increase of 3%-5% compared to the control group and can predict fermentation trends in real-time [3] - Revenue from synthetic biology products reached 48.8 million yuan in the first three quarters of 2025, with improved order conditions compared to the previous year [3] - The company expects significant revenue growth in synthetic biology products as production capacity increases and market expansion continues [3] Group 4: Management's Strategic Focus - The management plans to deepen technological innovation, optimize industrial layout, and enhance operational quality to reward shareholders' trust and support [4] - Chuaning Bio aims to become a significant innovative force in the global biotechnology sector, creating sustainable value for shareholders [4]

格隆汇12月16日丨川宁生物(301301.SZ)公布，收到四川科伦药业股份有限公司（下称"科伦药业"）及其 控制的成都科伦宁辉企业管理合伙企业（有限合伙）（下称"科伦宁辉"）（前两者以下统称"控股股 东"）分别出具的《关于自愿延长限售股份锁定期的承诺函》，控股股东基于对公司未来发展前景的信 心和对公司内在价值的认可，同时本着对中小股东负责的态度，以实际行动维护资本市场稳定和公司股 东利益，进一步促进公司持续、稳定、健康发展，增强投资者信心，自愿延长其所持有川宁生物的首次 公开发行前限售股份（下称"首发前限售股"）的锁定期。 ...

证券代码：301301 证券简称：川宁生物 公告编号：2025-040 伊犁川宁生物技术股份有限公司 关于控股股东追加承诺自愿延长股份限售期的公告 股东四川科伦药业股份有限公司和成都科伦宁辉企业管理合伙企业(有限 合伙)保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 伊犁川宁生物技术股份有限公司（以下简称"川宁生物"或"公司"）于 2025 年 12 月 16 日收到四川科伦药业股份有限公司（下称"科伦药业"）及其控制的 成都科伦宁辉企业管理合伙企业（有限合伙）（下称"科伦宁辉"）（前两者以下 统称"控股股东"）分别出具的《关于自愿延长限售股份锁定期的承诺函》，控股 股东基于对公司未来发展前景的信心和对公司内在价值的认可，同时本着对中小 股东负责的态度，以实际行动维护资本市场稳定和公司股东利益，进一步促进公 司持续、稳定、健康发展，增强投资者信心，自愿延长其所持有川宁生物的首次 公开发行前限售股份（下称"首发前限售股"）的锁定期。具体情况如下： 一、追加承诺股东基本情况介绍 （一）基本信息 1、科伦药业基 ...

Core Insights - Chuaning Bio, a leader in synthetic biology, won the "Top 50 New Quality Productivity Awards" at the 19th Listed Company Value Forum, reflecting its strong financial performance and innovative capabilities [2] Group 1: Company Overview - Chuaning Bio operates in the pharmaceutical manufacturing industry and is located in the core area of the Belt and Road Initiative [3] - The company focuses on a dual-driven strategy of "biological fermentation" and "synthetic biology," primarily engaged in the R&D and industrialization of biological fermentation technology and synthetic biology products [3] - Key products include thiocyanate erythromycin, 6-APA, potassium penicillin G, cephalosporin intermediates, ursodeoxycholic acid, and rosmarinic acid, with several products ranking among the top globally in production [3] Group 2: Financial Performance - As of the 2024 annual report, Chuaning Bio's net profit increased from approximately 110 million to 1.4 billion [4] - By June 2025, the company completed its third dividend distribution in its third year post-IPO, with a total dividend amount of 1.3 billion, fully covering the raised funds of 1.1 billion [4] Group 3: Product Development and Market Position - Chuaning Bio's synthetic biology products currently include rosmarinic acid, 5-hydroxytryptophan, ergothioneine, squalene, and inositol, with the star product ergothioneine already on the market [3] - The company is actively expanding its market presence, particularly in cosmetics and health products, while its synthetic biology base is still in the capacity ramp-up phase [3]

Core Viewpoint - The company Chuaning Biological is advancing its production of inositol (Vitamin B8) using synthetic biology technology, which offers cost advantages over traditional extraction methods. The product has received feed additive licenses and is widely used in aquaculture and livestock feed. Group 1: Company Developments - Chuaning Biological has implemented synthetic biology technology for inositol production, showcasing innovations in strain design and fermentation processes [2] - The technology has reached industrial application, although specific cost data is considered a commercial secret [2] - The company is currently in the capacity ramp-up phase at its synthetic biology base, with production capacity and sales forecasts for next year subject to market order conditions [2] Group 2: Product Applications and Market Position - Inositol has been licensed as a feed additive and is extensively applied in aquaculture and livestock feed [2] - The company has not disclosed specific customer information due to commercial confidentiality and compliance with information disclosure regulations [2] - Chuaning Biological is committed to advancing the industrialization of synthetic biology and will provide updates through official disclosure channels [2]

（文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：流感病毒蔓延，公司的抗生素对其有辅助治疗的作用 吗？ 川宁生物（301301.SZ）12月11日在投资者互动平台表示，尊敬的投资者，您好！公司作为抗生素中间 体生产企业，主要产品包括硫氰酸红霉素、头孢类中间体、青霉素中间体等，上述产品均用于合成抗菌 类药物。若流感患者出现细菌性并发症（如细菌性肺炎），临床医生可能根据实际情况使用抗生素类药 物进行辅助治疗。公司产品系上述抗生素药物的上游中间体。感谢您对公司的关注！ ...